Refine
Year of publication
Document Type
- Article (11)
- Preprint (2)
- Conference Proceeding (1)
- Doctoral Thesis (1)
- Working Paper (1)
Has Fulltext
- yes (16)
Is part of the Bibliography
- no (16)
Keywords
- Alleles (1)
- Antisense-Nucleinsäuren (1)
- Antisense-Oligonucleotide (1)
- Artifizielle Ribonucleasen (1)
- Bipolar disorder (1)
- Clinical Trials and Observations (1)
- Consortia (1)
- DNS (1)
- Depression (1)
- Etiology (1)
Institute
Iron is an essential co-factor for cellular processes. In the immune system, it can activate macrophages and represents a potential therapeutic for various diseases. To specifically deliver iron to macrophages, iron oxide nanoparticles are embedded in polymeric micelles of reactive polysarcosine-block-poly(S-ethylsulfonyl-l-cysteine). Upon surface functionalization via dihydrolipoic acid, iron oxide cores act as crosslinker themselves and undergo chemoselective disulfide bond formation with the surrounding poly(S-ethylsulfonyl-l-cysteine) block, yielding glutathione-responsive core cross-linked polymeric micelles (CCPMs). When applied to primary murine and human macrophages, these nanoparticles display preferential uptake, sustained intracellular iron release, and induce a strong inflammatory response. This response is also demonstrated in vivo when nanoparticles are intratracheally administered to wild-type C57Bl/6N mice. Most importantly, the controlled release concept to deliver iron oxide in redox-responsive CCPMs induces significantly stronger macrophage activation than any other iron source at identical iron levels (e.g., Feraheme), directing to a new class of immune therapeutics.
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.
Bipolar disorder (BD) is a major psychiatric illness affecting around 1% of the global population. BD is characterized by recurrent manic and depressive episodes, and has an estimated heritability of around 70%. Research has identified the first BD susceptibility genes. However, the underlying pathways and regulatory networks remain largely unknown. Research suggests that the cumulative impact of common alleles with small effects explains only around 25–38% of the phenotypic variance for BD. A plausible hypothesis therefore is that rare, high penetrance variants may contribute to BD risk. The present study investigated the role of rare, nonsynonymous, and potentially functional variants via whole exome sequencing in 15 BD cases from two large, multiply affected families from Cuba. The high prevalence of BD in these pedigrees renders them promising in terms of the identification of genetic risk variants with large effect sizes. In addition, SNP array data were used to calculate polygenic risk scores for affected and unaffected family members. After correction for multiple testing, no significant increase in polygenic risk scores for common, BD-associated genetic variants was found in BD cases compared to healthy relatives. Exome sequencing identified a total of 17 rare and potentially damaging variants in 17 genes. The identified variants were shared by all investigated BD cases in the respective pedigree. The most promising variant was located in the gene SERPING1 (p.L349F), which has been reported previously as a genome-wide significant risk gene for schizophrenia. The present data suggest novel candidate genes for BD susceptibility, and may facilitate the discovery of disease-relevant pathways and regulatory networks.
Die Entwicklung künstlicher Ribonucleasen bietet das Potential, Werkzeuge für die Biotechnologie und langfristig neuartige Pharmaka bereitzustellen. 2-Aminobenzimidazole haben sich als metallfreie Katalysatoren zur unspezifischen Spaltung von Ribonucleinsäuren bewährt. In der vorliegenden Arbeit sollte das Konzept von künstlichen Ribonucleasen auf Basis dieser Molekülklasse auf seine Tragfähigkeit gerprüft werden. Außerdem sollten weitere mechanistische Erkenntnisse über die Katalyse der RNA-Hydrolyse durch 2-Aminobenzimidazole gewonnen werden. Hierzu wurden kupplungsfähige 2-Aminobenzimidazol-Derivate hergestellt und anschließend an RNA-Liganden gekuppelt. Diese Konjugate wurden auf ihre Spaltaktivität gegenüber RNA bei physiologischen Bedingungen sowie auf ihre Substrat- und Ortsspezifität getestet. Zunächst wurden Tripeptidkonjugate synthetisiert und untersucht. Hierbei konnte eine gegenüber den unkonjugierten Spezies erhöhte Affinität der Konjugate zum Substrat festgestellt werden. Auch wurde gezeigt, dass 2-Aminobenzimidazole, die in wässriger Lösung zur Aggregation neigen, auch als Einzelmoleküle in der Lage sind, die RNA-Hydrolyse zu katalysieren. Die Substrat- und Ortsspezifität der Tripeptidkonjugate ließ jedoch zu wünschen übrig. Durch die Konjugation von 2-Aminobenzimidazol-Derivaten an Antisense-DNA gelang schließlich die sequenz- und ortsspezifische Affinitätsspaltung von RNA mit beachtlicher Aktivität. Damit war die Tragfähigkeit des Konzepts bewiesen. Ferner konnten durch die weitere Untersuchung der Konjugate starke Indizien gewonnen werden, die das Modell, auf dem die Auswahl der 2-Aminobenzimidazole als katalytische Einheit beruht, stützen.
We demonstrate the occurrence of canonical suppression associated with the conservation of an U(1)-charge in current transport models. For this study a pion gas is simulated within two different transport approaches by incorporating inelastic and volume-limited collisions pi pi leftrightarrow K bar-K for the production of kaon pairs. Both descriptions can dynamically account for the suppression in the yields of rare strange particles in a limited box, being in full accordance with a canonical statistical description.
Bipolar disorder (BD) is a highly heritable neuropsychiatric disease characterized by recurrent episodes of mania and depression. BD shows substantial clinical and genetic overlap with other psychiatric disorders, in particular schizophrenia (SCZ). The genes underlying this etiological overlap remain largely unknown. A recent SCZ genome wide association study (GWAS) by the Psychiatric Genomics Consortium identified 128 independent genome-wide significant single nucleotide polymorphisms (SNPs). The present study investigated whether these SCZ-associated SNPs also contribute to BD development through the performance of association testing in a large BD GWAS dataset (9747 patients, 14278 controls). After re-imputation and correction for sample overlap, 22 of 107 investigated SCZ SNPs showed nominal association with BD. The number of shared SCZ-BD SNPs was significantly higher than expected (p = 1.46x10-8). This provides further evidence that SCZ-associated loci contribute to the development of BD. Two SNPs remained significant after Bonferroni correction. The most strongly associated SNP was located near TRANK1, which is a reported genome-wide significant risk gene for BD. Pathway analyses for all shared SCZ-BD SNPs revealed 25 nominally enriched gene-sets, which showed partial overlap in terms of the underlying genes. The enriched gene-sets included calcium- and glutamate signaling, neuropathic pain signaling in dorsal horn neurons, and calmodulin binding. The present data provide further insights into shared risk loci and disease-associated pathways for BD and SCZ. This may suggest new research directions for the treatment and prevention of these two major psychiatric disorders.